Fasenra® and Nucala®: Approved Therapies for EGPA скачать в хорошем качестве

Fasenra® and Nucala®: Approved Therapies for EGPA

0:00 5:44 Survey question: Are you currently taking any anti-IL-5 drugs 6:25 Understanding EGPA 10:08 Cumulative clinical manifestations in 354 patients with EGPA 12:31 Treatment of EGPA 17:34 Survey question: Is asthma and/or sinus/nasal disease a significant part (problem) of your EGPA? 18:46 Treating asthma 22:06 Survey: Are you stuck on prednisone to control your EGPA? 23:48 The role of interleukin 5 (IL-5) in asthma / EGPA 25:05 How anti-IL-5 drugs work chemically in the body 27:03 The MIRRA Trial / Comparing mepolizumab to placebo 31:03 Summary of the MIRRA Trial 32:24 The MANDARA trial of benralizumab vs. mepolizumab for treatment of EGPA 36:07 Summary of the MANDARA trial 37:31 Data from the VCRC EGPA Registry 39:12 Tips for prescribing benralizumab or mepolizumab for EGPA 42:17 Q: Is there a difference between the doses of the anti-IL-5 drugs for asthma and EGPA? 43:34 Q: If Nucala doesn’t work what about switching to Fasenra? 45:31 Q: Jennifer Gordon’s story with EGPA and treatments. 47:05 Q: How do you make the decision to try the drug, or switch to these drugs? 51:05 Q: Will I have to take these drugs for the rest of my life? 55:12 Q: Is Tezepelumab being used to treat EGPA? 56:38 Join the VPPRN to get involved in clinical studies. Fasenra® and Nucala®: Approved Therapies for EGPA Recorded December 2024